Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; EA7293, Stress Vasculaire et Tissulaire en Transplantation, Université de Strasbourg, Faculté de Pharmacie, Illkirch, France.
Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Ann Thorac Surg. 2014 Jul;98(1):362-71. doi: 10.1016/j.athoracsur.2014.04.014. Epub 2014 May 22.
Risk factors for lung cancer in lung transplant recipients are a history of smoking and immunosuppression, to which adds increasing use of lungs from donors with a smoking history. The three typical presentations are incidental diagnosis on the explanted lung, concerning less than 2%; lung cancer developing on the lung graft, accounting for less than 1%; and incidence of lung cancer on the native lung, estimated at 9%. Treatment along available guidelines may be hampered by decreased lung function owing to chronic rejection or adverse effects of immunosuppression. Prognosis is comparable to a general population in resected stage I cancer and is less favorable in advanced stages.
肺移植受者肺癌的风险因素包括吸烟史和免疫抑制，此外，还包括越来越多地使用有吸烟史供体的肺。三种典型表现为移植肺的偶然诊断，占比小于 2%；肺移植后肺癌，占比小于 1%；以及原发性肺癌，估计为 9%。由于慢性排斥反应或免疫抑制的不良反应，可能会根据现有指南治疗而受到限制。肺功能下降。切除的 I 期癌症的预后与一般人群相当，而在晚期则不太有利。
